☆ 4.8 Meeting Abstract

Results of two phase I multicenter trials of AZD5363, an inhibitor of AKT1, 2 and 3: Biomarker and early clinical evaluation in Western and Japanese patients with advanced solid tumors.

CANCER RESEARCH (2013)

期刊

CANCER RESEARCH

卷 73, 期 8, 页码 -

出版社

AMER ASSOC CANCER RESEARCH

DOI: 10.1158/1538-7445.AM2013-LB-66

关键词

-

类别

Oncology

向作者/读者索取更多资源

Protocol

Reagent

作者

我是这篇论文的作者

点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8

评分不足

次要评分

新颖性

-

重要性

-

科学严谨性

-

评价这篇论文

推荐

Article Oncology

Phase Ia/Ib Study of the Selective MET Inhibitor, Savolitinib, in Patients with Advanced Solid Tumors: \nSafety, Efficacy, and Biomarkers

Yakun Wang, Tianshu Liu, Gongyan Chen, Jifang Gong, Yuxian Bai, Tao Zhang, Nong Xu, Li Liu, Jianming Xu, Jianxing He, Yunpeng Liu, Li Zhang, Da Jiang, Mengzhao Wang, Jianhua Chang, Wei Li, Chunmei Bai, Jinghong Zhou, Jian Wang, Yongxin Ren, Liya Zhang, Weiguo Su, Baorui Liu, Lin Shen

Summary: This study aimed to confirm the recommended phase II dose (RP2D) of savolitinib in Chinese patients and explore the overall benefits in tumors with c-Met aberration. The results showed that response was observed in gastric cancer patients with MET amplification and target lesion shrinkage was observed in NSCLC patients with MET exon 14 skipping mutation.

ONCOLOGIST (2022)

添加到收藏夹

Article Oncology

A Multicenter, Open-Label, Phase I/II Study of FN-1501 in Patients with Advanced Solid Tumors

Gary Edward Richardson, Raed Al-Rajabi, Dipesh Uprety, Anis Hamid, Stephen K. Williamson, Joaquina Baranda, Hirva Mamdani, Ya-Li Lee, Li Li, Xingli Wang, Xunwei Dong

Summary: FN-1501, a novel intravenous FLT3 inhibitor, has shown potential efficacy and safety for patients with advanced solid tumors. The maximum tolerated dose (MTD) of FN-1501 was determined to be 170 mg, demonstrating reasonable safety, tolerability, and preliminary activity against solid tumors.

CANCERS (2023)

添加到收藏夹

Article Gastroenterology & Hepatology

Cabozantinib in Japanese patients with advanced hepatocellular carcinoma: Final results of a multicenter phase II study

Naoya Kato, Masatoshi Kudo, Kaoru Tsuchiya, Atsushi Hagihara, Kazushi Numata, Hiroshi Aikata, Yoshitaka Inaba, Shunsuke Kondo, Kenta Motomura, Naohiro Okano, Masafumi Ikeda, Manabu Morimoto, Shingo Kuroda, Akiko Kimura

Summary: Cabozantinib demonstrated efficacy and manageable safety profile in Japanese patients with advanced HCC. The median PFS was 7.4 months in the prior-sorafenib cohort and 3.6 months in the sorafenib-naive cohort. Disease control rate was 85.0% and 64.3% in the prior-sorafenib and sorafenib-naive cohorts, respectively. The most common adverse events were palmar-plantar erythrodysesthesia syndrome, diarrhea, hypertension, and decreased appetite. No new safety concerns were identified.

HEPATOLOGY RESEARCH (2023)

添加到收藏夹

Article Oncology

High SAA1 Expression Predicts Advanced Tumors in Renal Cancer

Sen Li, Yongbiao Cheng, Gong Cheng, Tianbo Xu, Yuzhong Ye, Qi Miu, Qi Cao, Xiong Yang, Hailong Ruan, Xiaoping Zhang

Summary: Renal cell carcinoma (RCC) is the most frequent malignant tumor of the kidney, with 30% of patients being diagnosed at an advanced stage. Clear cell renal cell carcinoma (ccRCC) is the most common subtype, and SAA1 has been identified as a potential diagnostic and prognostic marker for advanced ccRCC. Studies show that high levels of SAA1 are associated with poor overall and disease-free survival times in advanced ccRCC patients. Targeting SAA1 may offer a novel therapeutic approach for these patients.

FRONTIERS IN ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Real-world clinical practice for advanced non-small-cell lung cancer in the very elderly: A retrospective multicenter analysis

Takahiro Fukushima, Yoshitaka Oyamada, Shinnosuke Ikemura, Shigenari Nukaga, Takashi Inoue, Daisuke Arai, Keiko Ohgino, Aoi Kuroda, Kota Ishioka, Fumio Sakamaki, Yusuke Suzuki, Hideki Terai, Hiroyuki Yasuda, Ichiro Kawada, Koichi Fukunaga, Kenzo Soejima

Summary: This study aimed to investigate the treatment of advanced NSCLCs in patients aged 80 and over and identify therapies that can improve their prognosis. Biomarker-matched therapy was found to be effective, while the effectiveness of chemotherapy for biomarker-negative/unknown patients was questionable.

CLINICAL LUNG CANCER (2022)

添加到收藏夹

Article Gastroenterology & Hepatology

Endoscopic resection for gastric submucosal tumors: Japanese multicenter retrospective study

Satoki Shichijo, Nobutsugu Abe, Hirohisa Takeuchi, Ken Ohata, Yohei Minato, Kazutoshi Hashiguchi, Kingo Hirasawa, Shoichi Kayaba, Hirohiko Shinkai, Hideki Kobara, Takeshi Yamashina, Tsukasa Ishida, Hideyuki Chiba, Hiroyuki Ono, Hirohito Mori, Noriya Uedo

Summary: Limited information is available on the efficacy and safety of endoscopic resection (ER) of gastric submucosal tumors (SMTs) in Japanese endoscopic practice where ER for gastric tumors is extremely popular. The study aimed to elucidate the current scenario of ER for gastric SMTs in Japanese endoscopic practice. Results showed an increasing trend in ER performance for gastric SMTs in Japan, with high feasibility and common pathology of gastrointestinal stromal tumors, without recurrence observed during the follow-up period.

DIGESTIVE ENDOSCOPY (2023)

添加到收藏夹

Article Gastroenterology & Hepatology

Serum matrix metalloproteinase-7 in biliary atresia: A Japanese multicenter study

Hirotaka Sakaguchi, Ken-ichiro Konishi, Ryosuke Yasuda, Hideyuki Sasaki, Koichiro Yoshimaru, Takahisa Tainaka, Suguru Fukahori, Yukihiro Sanada, Itaru Iwama, Hiromichi Shoji, Masahiro Kinoshita, Toshiharu Matsuura, Jun Fujishiro, Hiroo Uchida, Masaki Nio, Yushiro Yamashita, Tatsuki Mizuochi

Summary: This study found that serum MMP-7 concentration is a useful marker for diagnosing BA in Japanese infants, but it cannot predict the need for liver transplantation within a year.

HEPATOLOGY RESEARCH (2022)

添加到收藏夹

Review Oncology

Umbrella review of basket trials testing a drug in tumors with actionable genetic biomarkers

Alyson Haslam, Timothee Olivier, Jordan Tuia, Vinay Prasad

Summary: The utilization of basket trials in oncology has increased, but the overall response rate is low and varies widely depending on tumor type and genetic biomarker. It is unknown if the increasing options for less-common tumor types in basket trials have translated into patient benefit. There is also no strong correlation between the number of participants in each tumor basket and the incidence of the respective tumor.

BMC CANCER (2023)

添加到收藏夹

Article Oncology

Safety, pharmacokinetics, and preliminary efficacy of the PARP inhibitor talazoparib in Japanese patients with advanced solid tumors: phase 1 study

Yoichi Naito, Yasutoshi Kuboki, Masafumi Ikeda, Kenichi Harano, Nobuaki Matsubara, Shigeyuki Toyoizumi, Yuko Mori, Natsuki Hori, Takashi Nagasawa, Takahiro Kogawa

Summary: The study investigated the safety and preliminary antitumor activity of talazoparib in Japanese patients with advanced solid tumors, showing that single-agent talazoparib was well tolerated and had promising antitumor effects. The recommended phase 2 dose of talazoparib was established as 1 mg once daily, with a disease control rate of 44.4%.

INVESTIGATIONAL NEW DRUGS (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

Cabozantinib in Japanese patients with advanced hepatocellular carcinoma: a phase 2 multicenter study

Masatoshi Kudo, Kaoru Tsuchiya, Naoya Kato, Atsushi Hagihara, Kazushi Numata, Hiroshi Aikata, Yoshitaka Inaba, Shunsuke Kondo, Kenta Motomura, Junji Furuse, Masafumi Ikeda, Manabu Morimoto, Meguru Achira, Shingo Kuroda, Akiko Kimura

Summary: Cabozantinib 60 mg/day showed favorable efficacy and safety profile for Japanese patients with advanced hepatocellular carcinoma (HCC) who had previously received one or two lines of systemic anticancer therapy including sorafenib, especially for those who had received prior sorafenib treatment.

JOURNAL OF GASTROENTEROLOGY (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

Endoscopic full-thickness resection for gastric submucosal tumors: Japanese multicenter prospective study

Satoki Shichijo, Noriya Uedo, Atsushi Sawada, Kingo Hirasawa, Hirohisa Takeuchi, Nobutsugu Abe, Masaki Miyaoka, Kenshi Yao, Akira Dobashi, Kazuki Sumiyama, Tsukasa Ishida, Yoshinori Morita, Hiroyuki Ono

Summary: Endoscopic full-thickness resection for gastric submucosal tumors (SMT) of 11-30 mm in diameter is effective, with a 100% complete resection rate achieved in all 46 patients. Further validation in larger cohort studies is needed to determine long-term outcomes for patients with gastric gastrointestinal stromal tumors (GIST).

DIGESTIVE ENDOSCOPY (2023)

添加到收藏夹

Review Pharmacology & Pharmacy

Targeting Akt/PKB in pediatric tumors: A review from preclinical to clinical trials

Bruno Toson, Isadora S. Fortes, Rafael Roesler, Saulo F. Andrade

Summary: This article reviews the application of Akt inhibitors in pediatric cancers. The study demonstrates the impact of Akt inhibition on tumorigenesis and suggests targeting the PI3K/Akt/mTOR signaling pathway as an effective approach for treating pediatric tumors.

PHARMACOLOGICAL RESEARCH (2022)

添加到收藏夹

Review Oncology

Molecular response assessment using circulating tumor DNA (ctDNA) in advanced solid tumors

Jeffrey C. Thompson, Dylan G. Scholes, Erica L. Carpenter, Charu Aggarwal

Summary: The therapeutic landscape for patients with advanced malignancies has changed significantly in the past twenty years. While the availability of targeted therapies and immunotherapeutic options has improved response rates and survival for some patients, identifying the patients who will benefit from these therapies remains a clinical challenge. Cell-free circulating tumor DNA (ctDNA), which is already used for non-invasive tumor genotyping, offers a unique opportunity to assess therapeutic response and outcome in real-time. This article provides a summary and review of the use of molecular response for predicting outcomes in advanced cancer patients.

BRITISH JOURNAL OF CANCER (2023)

添加到收藏夹

Article Biochemistry & Molecular Biology

Clinical Significance of Molecular Subtypes in Western Advanced Gastric Cancer: A Real-World Multicenter Experience

Massimiliano Salati, Michele Ghidini, Matteo Paccagnella, Luca Reggiani Bonetti, Alessandro Bocconi, Andrea Spallanzani, Fabio Gelsomino, Francesca Barbin, Ornella Garrone, Bruno Daniele, Massimo Dominici, Antonio Facciorusso, Angelica Petrillo

Summary: Recent advances in molecular subtyping of gastric cancer have identified new clinically relevant biomarkers and potential therapeutic targets. Checkpoint inhibitors have also expanded treatment options, showing promising results in certain subgroups of gastric cancer patients. However, cytotoxic chemotherapy remains the only choice for patients who do not have these biomarkers. This study aims to investigate the prevalence, clinicopathologic features, and treatment outcomes of molecular subtypes in a new-diagnosed cohort of Western gastric cancer patients.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

添加到收藏夹

Article Oncology

Correlation between biomarkers and treatment outcomes in diverse cancers: a systematic review and meta-analysis of phase I and II immunotherapy clinical trials

Elena Fountzilas, Henry Hiep Vo, Peter Mueller, Razelle Kurzrock, Apostolia-Maria Tsimberidou

Summary: A meta-analysis of phase I/II clinical trials on immune checkpoint inhibitors (ICIs) showed that patients with biomarker-positive tumors had higher response rates and longer progression-free survival and overall survival compared to those with biomarker-negative tumors. These results suggest that biomarkers should be considered in selecting patients for ICI therapy.

EUROPEAN JOURNAL OF CANCER (2023)

添加到收藏夹

Meeting Abstract Oncology

A multi-modular phase I/II study of UCB6114, a first-in-class, fully human IgG4P anti-Gremlin-1 monoclonal antibody, as monotherapy and in combination with mFOLFOX6 or trifluridine/tipiracil, for patients with advanced gastrointestinal (GI) tumors

Debashis Sarker, Udai Banerji, Sarah Patricia Blagden, Natalie Cook, T. R. Jeffry Evans, Elizabeth Ruth Plummer, Marina Braun, Ann Cleverly, Nieves Diaz, Paul Jones, Ivan Matthews, Sophie Glatt

JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Individualized Prediction of Drug Response and Rational Combination Therapy in NSCLC Using Artificial Intelligence-Enabled Studies of Acute Phosphoproteomic Changes

Elizabeth A. Coker, Adam Stewart, Bugra Ozer, Anna Minchom, Lisa Pickard, Ruth Ruddle, Suzanne Carreira, Sanjay Popat, Mary O'Brien, Florence Raynaud, Johann de Bono, Bissan Al-Lazikani, Udai Banerji

Summary: The study demonstrates that acute protein perturbation caused by targeted anticancer drugs can be used to predict drug sensitivity and rational combination therapy. Machine-learning approaches show better prediction results compared to mutation-based methods. These findings have implications for treatment selection in the clinic.

MOLECULAR CANCER THERAPEUTICS (2022)

添加到收藏夹

Meeting Abstract Oncology

Targeting PI3K/AKT/mTOR pathway in platinum-resistant ovarian high-grade serous carcinoma: Translational analysis from the randomized phase II OCTOPUS trial

G. Giannone, D. Ennis, H. B. Mirza, Z. Cheng, J. McDermott, L-A. Lewsley, A. R. Clamp, R. A. Herbertson, R. M. Glasspool, J. Krell, S. Hinsley, U. Banerji, R. Riisnaes, S. Banerjee, I. McNeish

ANNALS OF ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Phase 1, dose-escalation study of guadecitabine (SGI-110) in combination with pembrolizumab in patients with solid tumors

Dionysis Papadatos-Pastos, Wei Yuan, Abhijit Pal, Mateus Crespo, Ana Ferreira, Bora Gurel, Toby Prout, Malaka Ameratunga, Maxime Chenard-Poirier, Andra Curcean, Claudia Bertan, Chloe Baker, Susana Miranda, Nahal Masrour, Wentin Chen, Rita Pereira, Ines Figueiredo, Ricardo Morilla, Ben Jenkins, Anna Zachariou, Ruth Riisnaes, Mona Parmar, Alison Turner, Suzanne Carreira, Christina Yap, Robert Brown, Nina Tunariu, Udai Banerji, Juanita Lopez, Johann de Bono, Anna Minchom

Summary: The combination of guadecitabine and pembrolizumab improves tumor sensitivity to immune checkpoint inhibitors and reverses previous resistance. This study demonstrates the safety and tolerability of the treatment regimen and observes some anticancer activity.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)

添加到收藏夹

Article Oncology

Cobalt-Doped g-C3N4 Nanosheets for One-Pot Synthesis of Imines under Mild Conditions

Sarah Halford, Gareth J. Veal, Stephen R. Wedge, Geoffrey S. Payne, Chris M. Bacon, Philip Sloan, Ilaria Dragoni, Kathrin Heinzmann, Sarah Potter, Becky M. Salisbury, Maxime Chenard-Poirier, Alastair Greystoke, Elizabeth C. Howell, William A. Innes, Karen Morris, Chris Plummer, Mihaela Rata, George Petrides, Hector C. Keun, Udai Banerji, Ruth Plummer

Summary: The purpose of this study is to investigate the effects of inhibiting lactate transport via monocarboxylate transporter 1 (MCT1) on tumor cells. The results from the dose-escalation part of the study showed that AZD3965, a first-in-class MCT1 inhibitor, is well tolerated at doses that produce target engagement.

CLINICAL CANCER RESEARCH (2023)

添加到收藏夹

Article Oncology

A Phase I/II Trial of Oral SRA737 (a Chk1 Inhibitor) Given in Combination with Low-Dose Gemcitabine in Patients with Advanced Cancer

Robert Jones, Ruth Plummer, Victor Moreno, Louise Carter, Desamparados Roda, Elena Garralda, Rebecca Kristeleit, Debashis Sarker, Tobias Arkenau, Patricia Roxburgh, Harriet S. Walter, Sarah Blagden, Alan Anthoney, Barbara J. Klencke, Mark M. Kowalski, Udai Banerji

Summary: The purpose of this study was to assess the safety, recommended dose, pharmacokinetic profile, and clinical activity of the novel checkpoint kinase 1 (Chk1) inhibitor SRA737 in combination with gemcitabine in patients with advanced solid tumors. The results showed that the combination of SRA737 and low-dose gemcitabine was well tolerated and demonstrated tumor responses in anogenital cancer and other solid tumors.

CLINICAL CANCER RESEARCH (2023)

添加到收藏夹

Article Oncology

A Phase 1/2 trial of SRA737 (a Chk1 inhibitor) administered orally in patients with advanced cancer

Rebecca Kristeleit, Ruth Plummer, Robert Jones, Louise Carter, Sarah Blagden, Debashis Sarker, Tobias Arkenau, Thomas R. Jeffry Evans, Sarah Danson, Stefan N. Symeonides, Gareth J. Veal, Barbara J. Klencke, Mark M. Kowalski, Udai Banerji

Summary: This study evaluated the novel Chk1 inhibitor SRA737 in patients with advanced solid tumors. The results showed that SRA737 was well tolerated, but single agent activity did not warrant further development. Therefore, further clinical development of SRA737 should be considered in combination with other drugs.

BRITISH JOURNAL OF CANCER (2023)

添加到收藏夹

Article Oncology

Combination ATR (ceralasertib) and PARP (olaparib) Inhibitor (CAPRI) Trial in Acquired PARP Inhibitor- Resistant Homologous Recombination-Deficient Ovarian Cancer

Stephanie L. Wethington, Payal D. Shah, Lainie Martin, Janos L. Tanyi, Nawar Latif, Mark Morgan, Drew A. Torigian, Diego Rodriguez, Simon A. Smith, Emma Dean, Susan M. Domchek, Ronny Drapkin, Ie-Ming Shih, Eric J. Brown, Wei -Ting Hwang, Deborah K. Armstrong, Stephanie Gaillard, Robert Giuntoli, Fiona Simpkins

Summary: The combination use of ATRi and PARPi can overcome PARPi resistance in high-grade serous ovarian cancer (HGSOC). This study evaluated the combination of olaparib and ceralasertib in patients with acquired PARPi-resistant HGSOC. The results showed tolerability and activity of the combination therapy in HR-deficient platinum-sensitive recurrent HGSOC, suggesting the potential of ceralasertib to resensitize PARPi-resistant tumors to olaparib.

CLINICAL CANCER RESEARCH (2023)

添加到收藏夹

Review Oncology

Clinical trial designs for evaluating and exploiting cancer evolution

Alvaro H. Ingles Garces, Nuria Porta, Trevor A. Graham, Udai Banerji

Summary: The evolution of drug-resistant cell subpopulations leads to treatment failure in cancer. Preclinical evidence suggests the possibility of influencing the response to subsequent treatments by modeling clonal evolution and collateral sensitivity. New therapy strategies and clinical trial designs are needed to steer cancer evolution. The competition between different subsets of drug-sensitive and resistant clones for nutrients/blood supply indicates the potential use of treatment paradigms based on cell-cell competition. This requires different clinical trial designs from the conventional practice and the integration of next-generation sequencing to improve the assessment of clinical response/resistance and exploit evolution.

CANCER TREATMENT REVIEWS (2023)

添加到收藏夹

Article Biochemical Research Methods

Unbiased differential proteomic profiling between cancer-associated fibroblasts and cancer cell lines

Rachel Lau, Lu Yu, Theodoros I. Roumeliotis, Adam Stewart, Lisa Pickard, Ruth Riisanes, Bora Gurel, Johann S. de Bono, Jyoti S. Choudhary, Udai Banerji

Summary: This study aimed to profile the proteome of cancer-associated fibroblasts (CAFs) and identify novel CAF biomarkers. The proteomic analysis revealed the upregulation of N-glycan biosynthesis and extracellular matrix proteins in CAFs, as well as the overexpression of heat shock protein & beta;-6 (HSPB6/HSP20) and cyclooxygenase 1 (PTGS1/COX1) as novel CAF biomarkers. Immunohistochemical analysis showed restricted expression of HSPB6 and PTGS1 in the stroma of tumor samples.

JOURNAL OF PROTEOMICS (2023)

添加到收藏夹

Article Multidisciplinary Sciences

Safety and anti-tumour activity of the IgE antibody MOv18 in patients with advanced solid tumours expressing folate receptor-alpha: a phase I trial

James Spicer, Bristi Basu, Ana Montes, Udai Banerji, Rebecca Kristeleit, Rowan Miller, Gareth J. J. Veal, Christopher J. J. Corrigan, Stephen J. J. Till, Mariangela Figini, Silvana Canevari, Claire Barton, Paul Jones, Sarah Mellor, Simon Carroll, Chris Selkirk, George Nintos, Vineet Kwatra, Ionut-Gabriel Funingana, Gary Doherty, Hannah J. J. Gould, Giulia Pellizzari, Mano Nakamura, Kristina M. M. Ilieva, Atousa Khiabany, Chara Stavraka, Jitesh Chauhan, Cheryl Gillett, Sarah Pinder, Heather J. J. Bax, Debra H. H. Josephs, Sophia N. N. Karagiannis

Summary: The study reports the results of a phase I dose escalation trial of MOv18 IgE, a chimeric first-in-class IgE antibody, in patients with tumours expressing folate receptor-alpha. The most common toxicity observed was transient urticaria and evidence of anti-tumour activity was observed in a patient with ovarian cancer.

NATURE COMMUNICATIONS (2023)

添加到收藏夹

Article Oncology

Relevance of ATM Status in Driving Sensitivity to DNA Damage Response Inhibitors in Patient-Derived Xenograft Models

Ankur Karmokar, Rebecca Sargeant, Adina M. Hughes, Hana Baakza, Zena Wilson, Sara Talbot, Sarah Bloomfield, Elisabetta Leo, Gemma N. Jones, Maria Likhatcheva, Luis Tobalina, Emma Dean, Elaine B. Cadogan, Alan Lau

Summary: The inactivation of DDR pathways provides new opportunities to target cancers. ATM, a key DDR kinase, is often mutated in various types of cancers. However, there is conflicting evidence on how ATM mutations in patients could enhance treatment responses to DDR inhibitors. This study aims to understand the correlation between different types of ATM mutations and protein expression/loss, and to identify ATM alterations that can predict sensitivity to DDR inhibitors in patient-derived xenograft models.

CANCERS (2023)

添加到收藏夹

Meeting Abstract Oncology

A study of evolutionary dynamics induced by carboplatin, olaparib and paclitaxel in high-grade serous ovarian cancer cell line models

Alvaro H. Ingles, Russo Garces, Salvatore Milite, Javier Fernandez-Mateos, Bingjie Chen, Lisa Pickard, Adam Stewart, Sara Diaz Sanchez, Rachel Lau, Erica Oliveira, Susana Banerjee, Andrea Sottoriva, Udai Banerji

CANCER RESEARCH (2022)

添加到收藏夹

Meeting Abstract Oncology

Phase I trial of the RAF/MEK clamp VS-6766 in combination with everolimus using an intermittent schedule with expansion in NSCLC across multiple KRAS variants.

Anna Rachel Minchom, Vicky Sanchez Perez, Cienne Morton, Thubeena Manickavasagar, George Nintos, Julia Elizabeth Lai-Kwon, Christina Guo, Nina Tunariu, Tom Parker, Toby Prout, Mona Parmar, Alison Joanne Turner, Laura Finneran, Emma Hall, Jonathan A. Pachter, Louis J. Denis, James F. Spicer, Udai Banerji

JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

Meeting Abstract Oncology

CONSENT - A RANDOMISED CONTROLLED TRIAL OF ENHANCED INFORMED CONSENT COMPARED TO STANDARD INFORMED CONSENT TO IMPROVE PATIENT UNDERSTANDING OF EARLY PHASE ONCOLOGY CLINICAL TRIALS - GBM COHORT (NONRANDOMISED) ANALYSIS

Abhijit Pal, Robert Daly, Shybi Mohamedkhan, Rafael Grochot, Sarah Stapleton, Christina Yap, Dimitrios Magkos, Bindumalini Rao Baikady, Anna Minchom, Udai Banerji, Johann De Bono, Deme Karikios, Frances Boyle, Juanita Lopez

NEURO-ONCOLOGY (2022)

添加到收藏夹

暂无数据

© Peeref 2019-2024. All rights reserved.